Efficacy of Peptide Anxiolytic Selank During Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation

Total Page:16

File Type:pdf, Size:1020Kb

Efficacy of Peptide Anxiolytic Selank During Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation 52 Bulletin of Experimental Biology and Medicine, Vol. 157, No. 1, May, 2014 PHARMACOLOGY AND TOXICOLOGY Effi cacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation L. G. Kolik, A. V. Nadorova, and M. M. Kozlovskaya Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 1567, No. 1, pp. 61-65, January, 2014 Original article submitted January 31, 2013 We studied the effects of selank on the development of symptoms of acute 48-h alcohol withdrawal in outbred rats drinking 10% ethanol as the only source of fl uid for 24 weeks. In alcohol-preferring animals (mean daily ethanol intake >5.0 g/kg) allowed free choice between 10% ethanol and water, single intraperitoneal injection of selank in a dose of 0.3 mg/kg eliminated anxiety induced by ethanol withdrawal in tests elevated plus maze and so- cial interaction tests and prevented the formation of mechanical allodynia without affecting ethanol consumption. The fi ndings suggest that selank is effective in eliminating of alcohol withdrawal symptoms in rats. Key Words: selank; alcohol withdrawal; anxiety; allodynia; rats Benzodiazepine anxiolytics temporary relieving man- by rapid onset of therapeutic effect and the absence of ifestation of psychopathological symptoms associ- undesirable side effects [4]. Experimental studies have ated with withdrawal syndrome play an important shown that it had a broad spectrum of psychotropic role in the complex medical therapy for alcoholism. activity and restored integrative activity of the CNS However, numerous side effects, such as respiratory impaired by neurotoxic factors of different genesis depression, excitement, potentiation of the narcogene [5]. The mechanism of the central action of selank effect of ethanol, and risk of drug dependence limit includes inhibition of enzyme degradation of enkeph- their use for pharmacological correction of withdraw- alins [1]. Signifi cant therapeutic effect of selank on al syndrome [8]. cognitive functions in combination with anxio lytic Apart from detoxifi cation procedures, schemes and stimulating effects have been demonstrated in of drug therapy for withdrawal syndrome include a clinical settings [6]. wide range of neuropsychotropic drugs (neuroleptics, Here we studied the effects of selank on behavior- antidepressants, and nootropics) that exert various side al manifestations of withdrawal syndrome in chroni- effects [3]. In light of this, the search for more specifi c cally alcoholized rats. and safe antialcoholic drugs for the relief of manifes- tations of alcohol withdrawal syndrome is an urgent MATERIALS AND METHODS problem. Selank, an original Russian peptide preparation, Experiments were carried out on 8-month-old male is effective in the treatment of generalized anxiety outbred rats with mean body weight 450-470 g in the disorders and asthenic conditions. It is characterized active phase of the experiment (Stolbovaya nursery). Alcohol abuse was modeled using the method for forced alcoholization of the animals providing a V. V. Zakusov Research Institute of Pharmacology, Russian Acad- emy of Medical Sciences, Moscow, Russia. Address for correspon- 10% ethanol solution as the sole source of fl uid for dence: [email protected]. L. G. Kolik 24 weeks. The animals were kept in individual ca- 0007 -4888/14/15710052 © 2014 Springer Science+Business Media New York L. G. Kolik, A. V. Nadorova, and M. M. Kozlovskaya 53 ges under standard vivarium conditions (vivarium of with previously published study protocol [9]. Anxio- V. V. Za kusov Research Institute of Pharmacology) lytic effect was assessed by lengthening the time of at 12-h light/dark cycle with free access to water and active social behavior of the “experimental” rat against chow. Changes in body weight and ethanol consump- the “resident” rat. tion (g/kg) were recorded weekly. During forced alco- Reaction threshold in response to mechanical holization, ethanol was consumed in physiologically stimulation was determined using calibrated von Frey signifi cant amount (6.5±0.2 and 5.0±0.3 g/kg at the fi laments (0.04, 0.07, 0.16, 0.40, 0.60, and 1.00 g), ap- start and end of the experiment, respectively). The ex- plied through a perforated fl oor to the rear paws of rats periments were performed on rats with stable alcoholic placed individually in Plexiglas chambers. Fast paw motivation that was evaluated by mean daily ethanol withdrawal was considered as a positive response and consumption (per 1 kg body weight per day) under stimulation was performed with a smaller fi lament or free choice between 10% ethanol and water. the same hair was used if the rat did not lick or shake After 48-h alcohol deprivation, the animals were the paw. Mechanical sensitivity threshold was deter- tested for alcohol deprivation effect (ADE) to assess mined by the minimum pressure that caused paw with- the nature of formation of alcohol dependence. Ethanol drawal response (3 of 5 attempts). Signifi cant decrease intake was recorded over the fi rst 90 min under condi- in sensitivity thresholds upon fi lament application was tions of free choice between water and 10% ethanol. regarded as mechanical allodynia [11]. Anxiety-related behavior in elevated plus maze The following preparations were used in the study: (EPM) test was evaluated as described previously selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) in the anxio- [10]. The animals were placed on central platform lytic dose of 0.3 mg/kg intraperitoneally (Institute of and basic spatial and temporal parameters (time spent Molecular Genetics, Russian Academy of Sciences) on the open arms, number of entries into the open and naloxone in a dose of 1.0 mg/kg intraperitoneally arms, number of entries into the closed arms) were (Sigma). Water was injected once 30 min before test- recorded over 300 sec. Increased number of entries ing in a ratio of 0.1 ml/100 g body weight of animal. into the open arms and time spent in open arms in the The study was performed in 5 groups of animals: absence of changes in motor activity (total number of intact rats (not offered ethanol; group 1), animals with entries into the open and closed arms) were consid- stable alcoholic motivation against the background ered as a manifestation of the anxiolytic effect. The of 10% ethanol consumption (group 2), and animals time in the open arms and number of entries in open with stable alcoholic motivation 48 h after ethanol arms were compared and calculated by the following withdrawal receiving water for injections (group 3), formulas: selank (group 4), or naloxone (group 5). The data were processed using the nonparametric time in open arms=time in the open Mann–Whitney U test. arms (sec)/300 sec×100% (1), number of entries into closed arms=number RESULTS of entries into closed arms/total number of entries into open and closed arms×100% (2). Evaluation of the effects of drugs on ADE severity showed that alcohol intake was not signifi cantly af- Social interaction test consists in evaluation of fected by selank (1.08±0.12 g/kg) in contrast to non- the time of active social behavior for rats in pairs (as selective opioid receptor antagonist naloxone (0.36± a measure of anxiety) to record both anxiogenic and 0.06 g/kg vs. 0.88±0.05 g/kg in controls; p<0.001). anxiolytic properties of the drug. Testing was per- Ethanol withdrawal in animals with stable alco- formed in an open fi eld (60×60 cm area surrounded holic motivation was associated with increased anxi- with 50-cm white walls and divided into 16 squares ety, which was seen from reduced time spent in open with a black marker) for 5 minutes under dimmed arms of EPM (p<0.05) and number of entries into open light. A pair of rats (“experimental” and “resident”; arms in comparison with the corresponding parameters difference in body weight did not exceed 10 g) kept in intact rats (Fig. 1). Naloxone had no effect on ani- in individual cells prior to the experiment were placed mal anxiety in EPM. Selank increased the time spent in unfamiliar surroundings of the open fi eld. The dura- (p<0.01) and entries into open arms (p<0.05), which tion of active behavior of “experimental” rat against attests to the anxiolytic effect of this drug. “resident” one (grooming, sniffi ng, rushing, wrestling, Ethanol withdrawal in animals with stable alco- chasing) was registered. Passive contact (sitting and/ holic motivation signifi cantly reduced (p<0.05) the or lying together) was not considered. Stress response time of social interaction. Selank prolonged the active to social interaction was evaluated based on individual contact of rats in pairs (p<0.01) suggesting the anxio- behavioral data of “experimental” rat in accordance lytic effect of this drug (Fig. 2). 54 Bulletin of Experimental Biology and Medicine, Vol. 157, No. 1, May, 2014 PHARMACOLOGY AND TOXICOLOGY Fig. 1. Effects of selank on EPM behavior of rats with stable alcoholic motivation 48 h after ethanol withdrawal. Ordinate: a) time spent in open arms, b) entries into the open arms. I: group 1 (intact rats); II: group 3; III: group 4; IV: group 5. p<0.05 in comparison with *group 1 (I), +group 3 (II). Each group included 9-10 animals. Fig. 2. Effects of selank on behavior of rats with stable alcoholic motivation 48 h after ethanol withdrawal in social interaction test. I: group 1; II: group 3; III: group 4; IV: group 5. Ordinate: time of social Fig. 3. Effects of selank on tactile sensitivity thresholds with interaction for rats in the pair. Total observation time (300 sec) is non-painful mechanical stimulation 48 h after ethanol withdrawal taken as 100%. xp<0.05 in comparison with group 1 (I); *p<0.01 in (median, 25th and 75th quantiles).
Recommended publications
  • Screening of 109 Neuropeptides on Asics Reveals No Direct Agonists
    www.nature.com/scientificreports OPEN Screening of 109 neuropeptides on ASICs reveals no direct agonists and dynorphin A, YFMRFamide and Received: 7 August 2018 Accepted: 14 November 2018 endomorphin-1 as modulators Published: xx xx xxxx Anna Vyvers, Axel Schmidt, Dominik Wiemuth & Stefan Gründer Acid-sensing ion channels (ASICs) belong to the DEG/ENaC gene family. While ASIC1a, ASIC1b and ASIC3 are activated by extracellular protons, ASIC4 and the closely related bile acid-sensitive ion channel (BASIC or ASIC5) are orphan receptors. Neuropeptides are important modulators of ASICs. Moreover, related DEG/ENaCs are directly activated by neuropeptides, rendering neuropeptides interesting ligands of ASICs. Here, we performed an unbiased screen of 109 short neuropeptides (<20 amino acids) on fve homomeric ASICs: ASIC1a, ASIC1b, ASIC3, ASIC4 and BASIC. This screen revealed no direct agonist of any ASIC but three modulators. First, dynorphin A as a modulator of ASIC1a, which increased currents of partially desensitized channels; second, YFMRFamide as a modulator of ASIC1b and ASIC3, which decreased currents of ASIC1b and slowed desensitization of ASIC1b and ASIC3; and, third, endomorphin-1 as a modulator of ASIC3, which also slowed desensitization. With the exception of YFMRFamide, which, however, is not a mammalian neuropeptide, we identifed no new modulator of ASICs. In summary, our screen confrmed some known peptide modulators of ASICs but identifed no new peptide ligands of ASICs, suggesting that most short peptides acting as ligands of ASICs are already known. Acid-sensing ion channels form a small family of proton-gated ion channels that belongs to the degenerin/epi- thelial Na+ channel (DEG/ENaC) gene family1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Nootropics- Memory Boosters
    Harikumar K. et al. / Journal of Pharmaceutical Biology, 6(1), 2016, 14-19. Journal of Pharmaceutical Biology www.jpbjournal.com e-ISSN - 2249-7560 Print ISSN - 2249-7579 NOOTROPICS- MEMORY BOOSTERS K.Hari Kumar*, Mitta Srija, D.K.Sandeep, Ramisetty Davarika, Gunda Sai Mounica Department of Pharmacology, Sri Venkateswara College of Pharmacy, R.V.S.Nagar, Chittoor-517127, Andhra Pradesh, India. ABSTRACT Nootropics also called as smart drug, memory enhancers, neuron enhancers, cognitive enhancers and intelligent enhancers are drugs, supplements, neutraceuticals and functional foods that provide one or more aspects of mental function. Specific effect can include improvement to working memory motivation or attention. Nootropics drugs are able to promote, enhance and protect cognitive functions. As cognition is the typically human higher activity of brain, nootropic concept looked quite appealing for scores of people dreaming to enjoy better and longer lasting mental activity and for drug maker keen to produce such enviable products. There are large number of drugs which can be used as nootropic agents and help to enhance memory of people. Nootropics offer lot of benefits for cognitive aptitude and brain health. Nootropics used for the treatment of Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, dementia and cognitive symptoms of schizophrenia. Keywords: Nootropics, Huntington’s disease, Dementia, Alzheimer’s disease. INTRODUCTION It is derived from Greek words “NOOS –Mind” But non-ADHD medications and supplements are more “Tropein – Turn/Bend”. They are also called as memory frequently used for performance enhancement. Many enhancers, Smart nutrients, Cerebroactive drugs and individuals use these drugs for performance enhancement cognition enhancers.
    [Show full text]
  • 17Th European Society for Biomedical Research on Alcoholism Congress 21-24 September 2019, Lille – Invited Talks and Symposia Abstracts
    Directeur de la rédaction Pr François Paille Rédacteur en chef Pr Amine Benyamina Rédacteurs associés Dr Philippe Batel Dr Ivan Berlin Dr Laurent Karila Pr Michel Lejoyeux Pr Mickaël Naassila Rédactrice Sciences humaines Pr Myriam Tsikounas Rédactrice Sciences psychologiques Pr Isabelle Varescon-Pousson Comité de rédaction Pr Georges Brousse Pr Olivier Cottencin Dr Michel Craplet Pr Jean-Bernard Daeppen Dr Jean-Michel Delile Pr Maurice Dematteis Dr Claudine Gillet th Dr Geneviève Lafaye 17 European Society for Biomedical Research Pr Michel Reynaud Dr Alain Rigaud Dr Marc Valleur on Alcoholism Congress Directeur de la publication Pr Mickael Naassila 21-24 September 2019, Lille Comité scientifique Pr Jean Adès Pr Thomas F. Babor Pr Jean-Louis Balmès Pr Maurice Bazot Dr Mats Berglund Pr Jacques Besson Pr Jean-Pierre Blayac Pr Jonathan D. Chick Mme Marie Choquet Pr Philippe de Witte Pr Michel Escande Pr Claude Got Dr Antoni Gual Pr Momar Gueye Pr Roger Henrion Pr Denise Kandel Pr Michel Le Moal Pr Karl Mann Mme Véronique Nahoum-Grappe Dr José Maria Neves Cardoso Pr Philippe-Jean Parquet Pr Jean-Louis Pedinielli Pr Falvio Poldrugo Pr Bernard Roques Pr John A. Talbott Pr Jean-Luc Vénisse Pr Lars von Knorring Pr Jacques Weill Pr Jean-Jacques Yvorel ISSN 2554-4853 Trimestriel Société Française PRINCEPS Éditions SEPTEMBRE-DÉCEMBRE 2019 - Tome 41, n° 3-4 d’Alcoologie !BSTRACTS CONGRÈS Pr Mickael Naassila* * President 17th ESBRA Meeting 17th European Society for Biomedical Research on Alcoholism congress 21-24 September 2019, Lille – Invited talks and Symposia abstracts Invited talks forward, such as combining training with neurostimulation.
    [Show full text]
  • Furosemide in the Treatment of Generalized Anxiety Disorder: Case Report and Review of the Literature
    International Research Journal of Pharmacy and Pharmacology (ISSN 2251-0176) Vol. 3(5) pp. 67-76, May 2013 Available online http://www.interesjournals.org/IRJPP Copyright © 2013 International Research Journals Case Report Furosemide in the treatment of generalized anxiety disorder: Case report and review of the literature *1 Dr. S. E. Oriaifo, 2Prof. E. K. I. Omogbai, 3Dr. N. I. Oriaifo, 3Dr. M. O. Oriaifo and 4Dr. E. O. Okogbenin *1Department of Pharmacology and Therapeutics, AAU, Ekpoma 2Department of Pharmacology and Toxicology, University of Benin, Benin-City, Nigeria. 3DepartmentOf Obstetrics and Gynaecology, Irrua Specialist Teaching Hoispital, Irrua 4Department of Psychiatry, Irrua Specialist Teaching Hospital, Irrua and Department of Psychiatry, Ambrose Alli University, Ekpoma. Accepted May 15, 2013 Generalised anxiety disorder (GAD) is the most common of the anxiety disorders seen in primary care and the 12-month prevalence in Nigeria may exceed 2.8%. The aim of this case-report is to highlight the use of furosemide in generalised anxiety disorder comorbid with dizziness in an adult female patient. Low-dose furosemide, 20mg to 40mg daily, attenuated the symptoms of generalised anxiety disorder, diagnosed in a young female patient with the Penn State Worry Questionnaire. It ameliorated the symptoms of pessimistic worry, muscle tension, dizziness, easy fatiguability, poor concentration, insomnia and irritability when used alone. Furosemide’s action in GAD may be due to its down- regulation of protein kinase C signalling which may be critical in establishing and maintaining a hyperglutamatergic state in key brain areas. Furosemide’s action may thus significantly reduce the simplified excitotoxicity index of glutamate/gamma-amino butyric acid.
    [Show full text]
  • Selank and Semax As Potential Hepatoprotectors in Medical
    Research Results in Pharmacology 5(4): 33–39 UDC: 615.331 DOI 10.3897/rrpharmacology.5.38769 Research Article Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis Alexey K. Petrovsky1, Nikolay A. Smirnov1, Vladimir P. Vdovichenko2, Tatiana B. Fedorova1, Edgar E. Kerbenev1, Vladimir N. Fedorov1 1 Yaroslavl State Medical University, 5 Revolyutsionnaya St., Yaroslavl 150000, Russian Federation 2 Grodno State Medical University, 80 Gorky St., Grodno 230009, Republic of Belarus Corresponding author: Alexey K. Petrovsky ([email protected]) Academic editor: Mikhail Korokin ♦ Received 2 August 2019 ♦ Accepted 24 October 2019 ♦ Published 16 December 2019 Citation: Petrovsky AK, Smirnov NA, Vdovichenko VP, Fedorova TB, Kerbenev EE, Fedorov VN (2019) Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis. Research Results in Pharmacology 5(4): 33–39. https://doi. org/10.3897/rrpharmacology.5.38769 Abstract Introduction: Drug-induced hepatitis is common in clinical practice. This problem is particularly relevant in the treat- ment of tuberculous infection, because for this purpose, up to 5–6 hepatotoxic drugs are used simultaneously for a long time, which often (in 15–20% of cases) leads to medical liver lesion. To protect the liver, Semax and Selank are offered – drugs of regulatory peptides group. Materials and Methods: The research was conducted on 96 outbred white male rats weighing 180–220 g. The experi- mental group included about 10 animals. Drug-induced hepatitis was simulated through the combined 21-day adminis- tration of isoniazid, rifampicin and ethanol. Semax and Selank, as well as Essentiale N and Mexidol (comparison drugs) were administered once a day during the experiment.
    [Show full text]
  • P.6.C. 003. the BDNF Mimetic, GSB-106, Produсes Long
    P.6.c. 003. The BDNF mimetic, GSB-106, produсes long-term analgesia and significant reduction of opiate withdrawal signs: comparison with dipeptide anxiolytic GB-115 effects in rats M.A. Konstantinopolsky ¹, T.A. Gudasheva ², L.G. Kolik ¹ V.V. Zakusov Institute of Pharmacology, ¹ Laboratory of Pharmacological Regulation of Addiction, ² Department of Medicinal Chemistry, Moscow, Russia [email protected] Introduction and Aim:. Antidepressants and Anxiolytics are used in clinical practice to eliminate the various features of opiate dependence. Some of them, benzodiazepine anxiolytics, especially, are able to produce the negative side effects [1]. New promising peptide origin medicines are safe and devoid of most disadvantages. Previously was shown, that cholecystokinin-4 (CCK-4) retro-analogue GB-115 (Ph|CH2|5-CO-Gly-L-Trp-NH2) exert anxiolytic-like activity and is capable to reduce the morphine withdrawal syndrome (WS) signs in rats [2,3], while the BDNF dipeptide mimetic GSB-106 [(bis-N-monosuccinil-seryl- lysine) hexamethylenediamide] exhibit antidepressant-like effect [4]. The present study has been initiated to investigate the potential antidepressant GSB-106 effects in comparison with those of anxiolytic GB-115 upon opiate WS, the pain thresholds and tolerance to morphine-induced analgesia in rats. The Methods. Incremental doses of morphine were injected i.p. to outbred male rats for 5 days followed by Naloxone (Du Pont De Nemours), 1mg/kg, to provoke acute WS. The peptides (GSB-106, 0.1-1.0 mg/kg; GB-115, 0.1-0.4 mg/kg;) have been injected i.p. 30 min before the test in the “open field” or daily 30 min before the morphine injections; after that the Total Index (TI) of WS was evaluated [5].
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0051350 A1 Zhu Et Al
    US 20170051350A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0051350 A1 Zhu et al. (43) Pub. Date: Feb. 23, 2017 (54) METHOD AND SYSTEM TO PREDICT (60) Provisional application No. 61/800,206, filed on Mar. RESPONSE TO TREATMENTS FOR 15, 2013, now abandoned, provisional application MENTAL DISORDERS No. 61/800,278, filed on Mar. 15, 2013, now aban doned. (71) Applicant: Pathway Genomics Corporation, San O Diego, CA (US) (72) Inventors: Guangdan Zhu, San Diego, CA (US); Publication Classification Cindy Wang, San Diego, CA (US); (51) Int. Cl Tanya Moreno, San Diego, CA (US); cio i/68 (2006.01) Andrew Hellman, San Diego, CA G06F 9/00 2006.01 (US); Alok Tomar, San Diego, CA ( .01) (US); Svetlana Ivanova Gramatikova, (52) U.S. Cl. San Diego, CA (US); Aditi Chawla, CPC ......... CI2O 1/6883 (2013.01); G06F 19/3431 San Diego, CA (US); Russell Kuo-fu (2013.01); G06F 19/704 (2013.01); C12O Del Tredici, San Diego, CA (US); (2013.01) Adrian Vilalta, San Diego, CA (US); K. David Becker, San Diego, CA (US); Michael Nova, San Diego, CA (US) (57) ABSTRACT (21) Appl. No.: 15/143,263 (22) Filed: Apr. 29, 2016 The present inventions relates to methods and assays to O O predict the response of an individual to a psychiatric treat Relatedelated U.S. Application DatUata ment and to a method to improve medical treatment of a (63) Continuation of application No. 13/917,573, filed on disorder, which is responsive to treatment with a psychiatric Jun. 13, 2013, now abandoned.
    [Show full text]
  • Tailor Made Compounding
    PEPTIDE CATALOG TAILOR MADE COMPOUNDING Phone: 1 859 887 0013 | Email: [email protected] Our Story | 04-05 MK-677 | 36 Peptide Fact Sheets | 06-55 Myristyl | 37 3-Desoxy DHEA | 08 NMN | 38 5-Amino-1MQ | 09 PEG-MGF | 39 Amlexanox | 10 Pentosan Polysulfate | 40 AMT | 11 PNC-27 | 41 Aniracetam | 12 PT-141 | 42 AOD 9604 | 13 PTD-DBM | 43 AOD 9604 + HA | 14 RG3, Methylcobalamin, NAD+ | 44 BPC-157 | 15 Sarms LGD-4033 | 45 Cerebrolysin | 16 Selank | 46 CJC-1295 | 17 Semax | 47 DHH-B | 18 Tesamorelin | 48 Dihexa | 19 Tesofensine | 49 DSIP | 20 Tetradecylthioacetic Acid (TTA) | 50 Eclomiphene | 21 Thymosin Alpha-1 | 51 Epitalon | 22 Thymosin Beta | 52 FGL (l) | 23 VIP | 53 GHK-Cu | 24 Zinc Thymulin | 54 TABLE OF TABLE Glycyrrhetinic Acid & Aminophylline Dosing Charts | 25 56-62 Transdermal Fat Loss Cream Licensed States | 64-65 IGF-1 | 26 TMC App | 66-67 Ipamorelin | 27 Contact Us | 68 iRGD | 28 Kisspeptin-10 | 29 KPV | 30 Leuphasyl | 31 LL-37 | 32 Malanotan II | 33 Met-Enkephalin | 34 MOTS-c | 35 CONTENTS Tailor Made Compounding was launched United States. Since the inception of TMC, in the U.S. in January of 2016. We have we have sourced and compounded over 40 since become a major contributor to unique peptides. We are proud to be the peptide medicines in the integrative first in the United States to offer health space. compounds like CJC 1295, Bremelanotide, OUR PT 141, BPC-157, and Epitalon and Through our compounding expertise, continue to introduce new and exciting knowledge and experience, we have compounds to our formulary.
    [Show full text]
  • P.6.C.014. ACTH4-10 Analogue Semax and Adamantane Derivative Hemantane Produce Significant Reduction of Withdrawal Signs in Morphine-Dependent Rats M.A
    P.6.c.014. ACTH4-10 analogue Semax and Adamantane derivative Hemantane produce significant reduction of withdrawal signs in morphine-dependent rats M.A. Konstantinopolsky ¹, L.G. Kolik ¹ V.V. Zakusov Institute of Pharmacology, ¹ Laboratory of Pharmacological Regulation of Addiction, Moscow, Russia, [email protected] Introduction :. The mechanism of opioid-like addiction has defined connections with DA-ergic reward system as well as with glutamate and NMDA systems of the brain. At the same time, some neuropeptides, namely, CCK analogues and one of taftsin derivatives, are able to reduce the severity of withdrawal signs in morphine-dependent rats [1,2] that give as the opportunity to suggest the modulating effect of these peptides in relation to opioid induced addiction. These facts have been considered when searching for new compounds with different action mechanisms to prevent and relieve the state of dependence. The main effects of Semax are its nootropic, neuroprotective and anxiolytic activity with the participation of serotonergic and CCK-receptors and, possible, BDNF [3], while Hemantane and Adamantane have an well-marked antiparkinsonian activity with the involvement of glutamatergic and NMDA receptor mechanisms [4]. Aim The present study was started to investigate the effects of the adrenocorticotropic hormone fragment, ACTH4-10, geptapeptide Semax (Inst. of Mol. Genetics RAN, Moscow) in comparison with those of Hemantane (N-adamant-2-yl-hexamethyleneimine hydrochloride, V.V. Zakusov Inst. of Pharmacology, Moscow) and Amantadine hydrochloride (1-aminoadamantane hydrochloride, Sigma-Aldrich), as a reference drug, upon opiate withdrawal syndrome (WS), tactile thresholds in “von Frey test”(Ugo Basile) and ambulation in the “open field”(OF) Methods.
    [Show full text]
  • Leu-Enkephalin Generally Labeled with Tritium in Studying the Selank Inhibiting Effect on the Enkephalin-Degrading Enzymes of Human Blood Plasma Yu
    Russian Journal of Bioorganic Chemistry, Vol. 30, No. 3, 2004, pp. 207–212. Translated from Bioorganicheskaya Khimiya, Vol. 30, No. 3, 2004, pp. 234–240. Original Russian Text Copyright © 2004 by Zolotarev, Sokolov, Kost, Vaskovsky, Myasoedov, Zozulya. Leu-Enkephalin Generally Labeled with Tritium in Studying the Selank Inhibiting Effect on the Enkephalin-Degrading Enzymes of Human Blood Plasma Yu. A. Zolotarev*, 1 O. Yu. Sokolov**, N. V. Kost**, B. V. Vaskovsky***, N. F. Myasoedov*, and A. A. Zozulya** *Institute of Molecular Genetics, Russian Academy of Sciences, pl. akademika Kurchatova 46, Moscow, 123182 Russia **National Research Center for Mental Health, Russian Academy of Medical Sciences, Moscow, Russia ***Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, GSP Moscow, 117997 Russia Received February 13, 2003; in final form, May 27, 2003 Abstract—A method of analysis of enkephalinase activity in blood plasma based on the application of Leu- enkephalin generally labeled with tritium at all its amino acid residues was developed. The method allows the simultaneous estimation of activity of several peptidases in microquantities of tissues. [G-3ç]Leu-enkephalin was prepared by the method of solid phase catalytic isotope exchange (120 Ci/mmol) and subjected to proteol- ysis by the treatment with blood plasma. The resulting radioactive metabolites were separated by HPLC in the presence of the mixture of unlabeled fragments of Leu-enkephalin as internal standards. It was shown that ami- nopeptidases, dipeptidylaminopeptidases, and dipeptidylcarboxypeptidases respond for approximately 80%, 2%, and 10% of the total enzymatic activity, respectively. The new pathway of degradation of Leu-enkephalin by carboxypeptidase that provides for ~6% of the total enkephalin-degrading activity was discovered.
    [Show full text]
  • Brain Health with Cerebrolysin and Other Peptides Cerebrolysin
    Brain Health with Cerebrolysin and Other Peptides Cerebrolysin ● A combination of nerve growth factors which aid in the repair and recovery of nerve cells within the brain and PNS. ● Neuro-protective/Neuro-regenerative: neurotrophic repair properties similar to NGF (nerve growth factors, BDNF) ● Neuropeptide; synthetic nootropic ● LMW can cross BBB/B-CSF Cerebrolysin: Therapeutic Uses ● Concussion/CTE, TBI ● Alzheimer’s Dementia, MCI ● CVA, TIA ● Mood Dysregulation Cerebrolysin in Dementia ● Decreases Beta Amyloid deposition ● Decreases Tau protein phosphorylation ● Increases synaptic density Cerebrolysin in Dementia ● Restores neuronal cyto-architecture ● Results in improved cognitive and behavioral performance ● To consider if ApoE→ E3/E4 or E4/E4 Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Z.H. Wei, et al. ● An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression. ● Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463–1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD. ● Cerebrolysin consists of 25% LMW peptides and free amino acids that easily penetrate the BBB and allow for rapid efficacy. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound Cerebrolysin™ E. Rockenstein, et al. ● Cerebrolysin has the ability of improving synaptic functioning and reducing amyloid deposition. ● Cbl decreased amyloid deposition; these effects accompanied by a reduction in perivascular microgliosis and astrogliosis and increased expression of markers of vascular fitness such as CD31 and ZO-1.
    [Show full text]